A Canadian company has revealed that it has a vaccine for COVID-19 just 20 days before the coronavirus sequence, a unique technology they hope to present and for the approval received and administration of the drug.
Brice Clark, CEO of Medicago, has that equal to clarinella can millions up to 10 doses per month. If the various steps are taken by the regulations, the vaccine will be available as early as November. An Israeli research laboratory has also found a vaccine, but according to Clark of Medicago, it is a reliable one thanks to a technique of trafficking that with the talk that is also in vaccines against seasonal flu. ‘There’s also a lot of work to be said that it’s missing the vaccine but it’s about different technologies. Some are vaccines on RNA or DNA that have not been validated for type of use, yet for Coronavirus.”
Come did Clark’s team create one so fast? Hen eggs were not valid, with the use of the bioreactor intended for protein and protein the vaccine. The traditional production of vaccine production a large amount of: according to Clark, their use is the, a long time and is anything but. Vaccine vaccines vaccines that do not target the virus that they aim to. It involves the insertion into the agrobacterium (soil bacterium) of a genetic sequence that is part of my set-up a produce the protein that can then biological. If the satonument virus mutates, come in the case of COVID-19, with a simple production update of the we will have a vaccine. “This is the fatra between us and the methods that egg eggs,” Clark added, “let’s go get the vaccine or the antibody to propagate the virus.”
At the genetic level, the use of plants and agrobacteria works faster than eggs and makes the vaccine much easier to produce on a large scale, which, in part, is why the U.S. Army has invested in the company. In 2010, the Defense Advanced Research Projects Agency put together a 100-million-dollar program dubbed Blue Angel to examine new discoveries in vaccine production. A big chunk of that money went to Medicago to build a facility in North Carolina, where it proved to be able to make a vaccine in just 20 days and then quickly increase production. Clark said he was very confident that as soon as they had the permits, they would be able to produce 10 million doses of vaccine per month. The only obstacles are now represented by the regulatory authorities. The company’s production method has not yet been approved by the FDA and will need to pass the scrutiny of some clinical trials before moving on to production.
“Thereis a lot of room for negotiation with the regulators,” Clarkadded, “I will not put words in his mouth, I will say that our intention is to move to Phase III by November allowing the vaccine to be made available to the public.”
The confirmation came from Anthony Fauci,director of the National Institute of Allergy and Infectious Disease at the National Institutes of Health. In a speech to the U.S. House Oversight and Reform Committee, he explained that testing for a vaccine, without specifying its manufacturer, would be possible within a few weeks, adding that for general administration the timing ranges from 12 to 18 months.